Celcuity Q2 FY26 net loss widens to $78.9 million; operating expenses climb to $66.1 million
CELC•R&D spending declines
R&D slipped to $31.1 million from $36.4 million, on lower VIKTORIA-1 trial costs and reduced license milestone expenses.
Quarterly loss and expenses widen
Celcuity posted a GAAP net loss of $78.9 million, or $1.44 a share, widening from $45.3 million a year earlier.
Total operating expenses climbed to $66.1 million from $44 million, as SG&A jumped to $35 million from $7.6 million.
Cash position and operating cash use
Cash, cash equivalents and short-term investments rose to $754 million at quarter-end; net cash used in operations increased to $55.4 million.
REVTORPYK clearance and launch target
Gedatolisib branded REVTORPYK won FDA clearance on July 14; Celcuity targets a late third-quarter 2026 U.S. launch.
